Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years who are generally well enough to carry out daily activities with little to no limitation (confirmed by a doctor's assessment scale called ECOG 0–1).
• People who have been diagnosed with colorectal cancer (bowel cancer) or pancreatic cancer confirmed by laboratory testing, who have had surgery to fully remove the tumour, and who have completed at least 4 rounds of chemotherapy after that surgery.
• People whose cancer was at a specific stage after surgery — for bowel cancer, stage IIIA, IIIB, or IIIC; for pancreatic cancer, stage I, II, or III — and whose tumour has a specific gene change (mutation) in the KRAS gene, in one of these forms: G12D, G12V, G12R, G12A, G12S, G12C, or G13D.
• People who have no signs of cancer returning or spreading, based on scans or imaging.
• People whose blood test results meet specific healthy ranges for immune cells, red blood cells, and platelets (confirm with trial site for exact values).
• People whose liver and kidney function blood test results are within acceptable ranges as set by the trial (confirm with trial site for exact values).
• People whose blood clotting test results are within acceptable ranges (confirm with trial site for exact values).
• People who are able to use reliable contraception or birth control throughout the trial, if there is any possibility of becoming pregnant.
• People who have signed a consent form agreeing to take part.
• People who are able to follow the trial schedule and attend all required follow-up appointments.

Who may not be able to join:

• People with bowel cancer whose tumour has a specific genetic feature called MSI-H or dMMR, or who have a BRAF gene mutation.
• People with pancreatic cancer that contains a type of tumour called a neuroendocrine tumour.
• People who have had another type of cancer in the past, unless it was a very early-stage cervical, skin, or bladder cancer that was treated, or another cancer that was fully treated at least 5 years before joining the trial.
• People who have previously received an anti-cancer vaccine or certain immune-based treatments that target specific proteins involved in immune regulation (such as anti-PD1, anti-PDL1, or anti-CTLA4 therapies).
• People who have HIV, hepatitis C (HCV), or hepatitis B (HBV) infection, or uncontrolled heart disease, uncontrolled asthma, uncontrolled stroke-related conditions, or any other condition that the trial doctor considers a reason to exclude participation.
• People who are currently taking immune-suppressing medications, including steroid medicines at doses above a certain level, and have taken them within the 2 weeks before joining.
• People with significant heart-related conditions, such as moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, certain serious irregular heartbeats requiring treatment, or an abnormal heart rhythm measurement on an ECG above specific thresholds.
• People with abnormal blood clotting, a tendency to bleed, or who are currently on blood-thinning or clot-dissolving treatment (low-dose aspirin or low-dose blood thinners used for prevention may be acceptable — confirm with trial site).
• People with an active infection, an unexplained high fever (38.5°C or above) in the 7 days before starting treatment, a very high white blood cell count, or wounds that are not healing due to ongoing infection.
• People who are pregnant or breastfeeding, or women who could become pregnant and have not had a negative pregnancy test within 7 days before joining.
• People whose substance use, or mental, psychological, or social circumstances, may affect their ability to give informed consent or properly take part in the trial.
• People with a known or suspected allergy to any of the medicines used in this trial.
• People who are unable to attend the required medical and immune-monitoring follow-up assessments.
• People who have previously received a transplanted organ or bone marrow/stem cell transplant from another person.
• People who are currently enrolled in another clinical trial involving an investigational treatment.

Important: Always verify eligibility with the trial site directly before applying.